BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 22414285)

  • 1. Is image registration of fluorodeoxyglucose-positron emission tomography/computed tomography for head-and-neck cancer treatment planning necessary?
    Fried D; Lawrence M; Khandani AH; Rosenman J; Cullip T; Chera BS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):748-54. PubMed ID: 22414285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy.
    Leclerc M; Lartigau E; Lacornerie T; Daisne JF; Kramar A; Grégoire V
    Radiother Oncol; 2015 Jul; 116(1):87-93. PubMed ID: 26088157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer.
    Guido A; Fuccio L; Rombi B; Castellucci P; Cecconi A; Bunkheila F; Fuccio C; Spezi E; Angelini AL; Barbieri E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):759-63. PubMed ID: 18834671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ¹⁸F-FDG-PET imaging in radiotherapy tumor volume delineation in treatment of head and neck cancer.
    Delouya G; Igidbashian L; Houle A; Bélair M; Boucher L; Cohade C; Beaulieu S; Filion EJ; Coulombe G; Hinse M; Martel C; Després P; Nguyen-Tan PF
    Radiother Oncol; 2011 Dec; 101(3):362-8. PubMed ID: 21885143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Mohamed ASR; Cardenas CE; Garden AS; Awan MJ; Rock CD; Westergaard SA; Brandon Gunn G; Belal AM; El-Gowily AG; Lai SY; Rosenthal DI; Fuller CD; Aristophanous M
    Radiother Oncol; 2017 Aug; 124(2):248-255. PubMed ID: 28774596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas.
    Chauhan D; Rawat S; Sharma MK; Ahlawat P; Pal M; Gupta G; Dewan A; Gupta M; Sharma S; Dodagoudar C; Pahuja A; Mitra S; Sharma SK
    J Cancer Res Ther; 2015; 11(4):746-51. PubMed ID: 26881512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.
    Scarfone C; Lavely WC; Cmelak AJ; Delbeke D; Martin WH; Billheimer D; Hallahan DE
    J Nucl Med; 2004 Apr; 45(4):543-52. PubMed ID: 15073248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of 18FDG-PET/CT in the management and gross tumor volume definition for radiotherapy of head and neck cancer; single institution experiences based on long-term follow-up].
    Hideghéty K; Cserháti A; Besenyi Z; Zag L; Gaál S; Együd Z; Mózes P; Szántó E; Csenki M; Rusz O; Varga Z; Dobi Á; Maráz A; Pávics L; Lengyel Z
    Magy Onkol; 2015 Jun; 59(2):103-10. PubMed ID: 26035157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
    Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor volume delineation in head and neck cancer with 18-fluor-fluorodeoxiglucose positron emission tomography: adaptive thresholding method applied to primary tumors and metastatic lymph nodes.
    Perez-Romasanta LA; Bellon-Guardia M; Torres-Donaire J; Lozano-Martin E; Sanz-Martin M; Velasco-Jimenez J
    Clin Transl Oncol; 2013 Apr; 15(4):283-93. PubMed ID: 22865325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

  • 13.
    van den Bosch S; Doornaert PAH; Dijkema T; Zwijnenburg EM; Verhoef LCG; Hoeben BAW; Kasperts N; Smid EJ; Terhaard CHJ; Kaanders JHAM
    Radiother Oncol; 2020 Jan; 142():107-114. PubMed ID: 31439447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer.
    Paulino AC; Koshy M; Howell R; Schuster D; Davis LW
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1385-92. PubMed ID: 15817341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between CT- and FDG-PET-defined target volumes for radiotherapy planning in head-and-neck cancers.
    Henriques de Figueiredo B; Barret O; Demeaux H; Lagarde P; De-Mones-Del-Pujol E; Kantor G; de Clermont-Gallerande H; Richaud P; Fernandez P
    Radiother Oncol; 2009 Dec; 93(3):479-82. PubMed ID: 19880207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
    Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18FDG] PET-CT-based intensity-modulated radiotherapy treatment planning of head and neck cancer.
    El-Bassiouni M; Ciernik IF; Davis JB; El-Attar I; Reiner B; Burger C; Goerres GW; Studer GM
    Int J Radiat Oncol Biol Phys; 2007 Sep; 69(1):286-93. PubMed ID: 17707283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers.
    Soto DE; Kessler ML; Piert M; Eisbruch A
    Radiother Oncol; 2008 Oct; 89(1):13-8. PubMed ID: 18555547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake.
    Due AK; Vogelius IR; Aznar MC; Bentzen SM; Berthelsen AK; Korreman SS; Loft A; Kristensen CA; Specht L
    Radiother Oncol; 2014 Jun; 111(3):360-5. PubMed ID: 24993331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.